Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF -4.64%75 Operating Cash Flow per Share is $-1.08 as of Jun. 2026. GuruFocus rates PROF with a GF Score™ of 75/100 and a GF Value™ of $10.59 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 649 Medical Devices & Instruments companies, Profound Medical ranks worse than 69.18% on this metric.
Profound Medical's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.31.
Profound Medical's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.08.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -1.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -1.20% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Profound Medical's Operating Cash Flow per Share or its related term are showing as below:
PROF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -1.2 Med: 5.05 Max: 19.8
Current: -1.2
During the past 12 years, Profound Medical's highest 3-Year average Operating Cash Flow per Share Growth Rate was 19.80% per year. The lowest was -1.20% per year. And the median was 5.05% per year.
PROF's 3-Year OCF Growth Rate is ranked worse than 69.18% of 649
companies
in the Medical Devices & Instruments industry
Industry Median: 12.3
vs PROF: -1.20
Profound Medical Operating Cash Flow per Share Related Terms
Profound Medical Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Profound Medical's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical Operating Cash Flow per Share Chart
PROF vs ABT, SYK, MDT: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, Profound Medical's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Profound Medical's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-1.08 mean?
Profound Medical (PROF) has a Operating Cash Flow per Share of $-1.08 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #449 out of 649 companies in the Medical Devices & Instruments industry, placing it in the top 69.2%.
Is Profound Medical's Operating Cash Flow per Share too high?
Profound Medical's current Operating Cash Flow per Share is $-1.08. Based on the distribution chart, Profound Medical ranks #449 out of 649 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Operating Cash Flow per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #449 out of 649 companies for Operating Cash Flow per Share. This places Profound Medical in the lower half of its industry. The industry median Operating Cash Flow per Share is 12.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.30, based on 649 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Operating Cash Flow per Share is $-1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.59, compared to a current price of $6.99 — trading 34% below its estimated fair value. The current Operating Cash Flow per Share is $-1.08. Profound Medical's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Profound Medical (PROF), the current Operating Cash Flow per Share is $-1.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $6.99 is trading 34% below its estimated GF Value™ of $10.59.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Operating Cash Flow per Share: $-1.08
GF Value™: $10.59 vs. price of $6.99 (34% below fair value)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
75GF Score
Get the complete analysis for PROF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
